Invitation to Korean companies

In June, Måns Österberg, Director Alliance Management will visit our collaboration partners in Korea to develop the projects further. There will also…

Meet us at Bio International, San Diego , June 13-16

In June, Iconovo will attend the conference Bio International to meet new customers and partners. Roger Lassing, VP Business Development, is happy to book…

Annual Report 2021 released

The Annual Report for 2021 is now available for download from Iconovo´s website. The Annual Report is in Swedish and an English version is yet to be …

ICOpre – the story behind a new, generic inhaler platform to Ellipta

Iconovo has developed a new and innovative dry powder inhaler platform - ICOpre - aimed for a global market. ICOpre is a pre-metered dry powder inhaler…

Iconovo AB presenterar på Stockholm Corporate Finance 13e Life Science Seminarium (only in Swedish)

Iconovo deltar på Stockholm Corporate Finance 13e Life Science Seminarium den 23 mars 2021, kl. 11.00 då VD Johan Wäborg presenterar senaste…

First granted ICOone® patent in India

Iconovo AB (publ) has been granted its first patent in India on the inhalation platform ICOone®. Iconovo has previously granted ICOone® patents…

Iconovo – Intervju Erik Penser Bank 17 februari 2021 (only in Swedish)

Iconovos VD Johan Wäborg intervjuas av aktieanalytiker Johan Löchen från Erik Penser Bank. Se videon youtu.be.     Kontakter Johan Wäborg,…

Iconovos vd Johan Wäborg kommenterar helårsresultatet för 2020 (only in Swedish)

Inhalationsbolaget Iconovo har idag publicerat bokslutskommunikén för 2020 som visar högre omsättningssiffror jämfört med året innan. Under…

VD Johan Wäborg presenterar Iconovo på Aktiedagen den 27 januari 2021 (only in Swedish)

Bolagspresentation av Iconovo från Aktiedagen den 27 januari 2021.   Kontakter Johan Wäborg, VD +46 707 78 51 71 …